New imaging test for liver scarring in fatty liver disease
Part of Digestive system clinical trials.
This study tests whether a new type of PET/CT scan can measure liver scarring (fibrosis) in people with fatty liver disease. It might help doctors check liver damage without needing repeated biopsies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a liver biopsy that shows nonalcoholic steatohepatitis (NASH), a type of fatty liver disease.
- You are 18 years or older.
- You are covered by a health insurance scheme.
- You do not have hepatitis B or C, or advanced liver damage with complications.
- You have not taken certain medications like corticosteroids, tamoxifen, amiodarone, or methotrexate.
- You have not drunk too much alcohol in the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This trial studies how well a special imaging test (68Ga-FAPI PET/MRI) can detect and evaluate hepatocellular carcinoma (HCC), a type of liver cancer. It may help doctors confirm diagnosis and plan next steps by seeing how the cancer takes up the tracer.
This study tests a new imaging scan (called 18F-FAPI PET/CT) that may help detect scarring in the lungs, heart, or blood vessels. If you have a heart, lung, or blood vessel condition that could cause scarring, this scan might show damage earlier and help doctors plan better treatment.
This trial uses a special PET scan (68Ga-FAPI) to see how well systemic therapy is working in people with advanced liver cancer that can't be removed by surgery. The goal is to find a better way to measure treatment effectiveness.
This study uses a special PET scan to look for inflammation in the brain related to fatty liver disease. It may help researchers understand how liver health affects brain function.
This study tests whether a new type of MRI scan can better detect and measure liver disease, including fatty liver and scarring, compared to standard CT scans. If you have chronic liver disease, this study may help improve how we diagnose and track it.
Hear when a new Non-alcoholic Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.